IL5 and arthritic joint disease: Notably, in patients with rheumatoid arthritis and concomitant asthma, the depletion of eosinophil with an anti–IL-5 antibody (mepolizumab) induced relapse of arthritis in a majority of cases (Andreev et al., 2020).